EffRx to Showcase Binosto® at WCO-IOF-ESCEO 2018 in Krakow, Poland

EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its

Learn More

European market-entry strategy for biopharma companies

The European pharmaceutical market offers many opportunities for U.S. biopharmaceutical companies. An early engagement as well as a visceral understanding of the heterogeneity of the European market are key to succeed. Partnering with EffRx Pharmaceuticals, a commercial-stage pharmaceutical company offers various advantages. Because of its diversity and non-bureaucratic access to a talented workforce, EffRx an

Learn More

Meet the EffRx Team at the 23rd Annual BIO-Europe International Conference from 6-8 November 2017 in Berlin

The 23rd Annual BIO-Europe International Conference is the “must-attend” event and Europe’s largest life science partnering conference. And EffRx will be there. The conference brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more. To arrange for a meeting, please

Learn More

Binosto Data Presented at the ASBMR Congress in Denver

EffRx Pharmaceuticals SA is proud to inform that the latest safety data on Binosto® were presented as a poster on Sunday, 10th of September 2017 at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting in Denver, Colorado, USA attended by more than 3,000 scientists from 70 countries. Binosto®, the world’s first

Learn More

Osteoporosis patients in Germany and Russia get access to Binosto®

EffRx launches Binosto® – the first and only buffered solution for the treatment of osteoporosis – in two more markets. Freienbach, Switzerland, 8. June 2017 – EffRx Pharmaceuticals SA today announced that physicians in Germany and Russia treating patients with postmenopausal osteoporosis have a new therapy option: buffered soluble alendronate (Binosto®). This novel formulation, which

Learn More

Paolo Agnoluzzi Appointed CFO of EffRx Pharmaceuticals

Freienbach, Switzerland, June 1st, 2017 – EffRx Pharmaceuticals SA announced today the appointment of Mr. Paolo Agnoluzzi as Chief Financial Officer effective June 1st, 2017. Mr. Agnoluzzi joined EffRx in August 2016 as Interim Chief Financial Officer and led the re-organization of the Finance Department. Among other achievements he executed a number of debt and

Learn More

Binosto data to be presented at the WCO-IOF-ESCEO Congress in Florence

EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy, from 23 to 26 March 2017. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue

Learn More

Bone markers as screening strategy for patient adherence to osteoporosis medications

IOF-ECTS Position Paper provides recommendations for the screening of adherence to oral bisphosphonates; proposes assessment using PINP and CTX bone turnover markers (BTMs) at baseline and after three months. Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue

Learn More

EffRx Pharmaceuticals | EffRx